Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
09 déc. 2024 19h30 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
02 déc. 2024 07h00 HE
|
Autolus Therapeutics plc
High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
12 nov. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
05 nov. 2024 09h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
28 oct. 2024 17h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
16 oct. 2024 09h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
19 sept. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
27 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
31 mai 2024 08h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
14 mai 2024 10h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress